Division of Interventional Neuroradiology, David Geffen School of Medicine, University of California, Los Angeles.
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles.
JAMA. 2019 Jul 16;322(3):252-263. doi: 10.1001/jama.2019.8286.
Randomized clinical trials suggest benefit of endovascular-reperfusion therapy for large vessel occlusion in acute ischemic stroke (AIS) is time dependent, but the extent to which it influences outcome and generalizability to routine clinical practice remains uncertain.
To characterize the association of speed of treatment with outcome among patients with AIS undergoing endovascular-reperfusion therapy.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study using data prospectively collected from January 2015 to December 2016 in the Get With The Guidelines-Stroke nationwide US quality registry, with final follow-up through April 15, 2017. Participants were 6756 patients with anterior circulation large vessel occlusion AIS treated with endovascular-reperfusion therapy with onset-to-puncture time of 8 hours or less.
Onset (last-known well time) to arterial puncture, and hospital arrival to arterial puncture (door-to-puncture time).
Substantial reperfusion (modified Thrombolysis in Cerebral Infarction score 2b-3), ambulatory status, global disability (modified Rankin Scale [mRS]) and destination at discharge, symptomatic intracranial hemorrhage (sICH), and in-hospital mortality/hospice discharge.
Among 6756 patients, the mean (SD) age was 69.5 (14.8) years, 51.2% (3460/6756) were women, and median pretreatment score on the National Institutes of Health Stroke Scale was 17 (IQR, 12-22). Median onset-to-puncture time was 230 minutes (IQR, 170-305) and median door-to-puncture time was 87 minutes (IQR, 62-116), with substantial reperfusion in 85.9% (5433/6324) of patients. Adverse events were sICH in 6.7% (449/6693) of patients and in-hospital mortality/hospice discharge in 19.6% (1326/6756) of patients. At discharge, 36.9% (2132/5783) ambulated independently and 23.0% (1225/5334) had functional independence (mRS 0-2). In onset-to-puncture adjusted analysis, time-outcome relationships were nonlinear with steeper slopes between 30 to 270 minutes than 271 to 480 minutes. In the 30- to 270-minute time frame, faster onset to puncture in 15-minute increments was associated with higher likelihood of achieving independent ambulation at discharge (absolute increase, 1.14% [95% CI, 0.75%-1.53%]), lower in-hospital mortality/hospice discharge (absolute decrease, -0.77% [95% CI, -1.07% to -0.47%]), and lower risk of sICH (absolute decrease, -0.22% [95% CI, -0.40% to -0.03%]). Faster door-to-puncture times were similarly associated with improved outcomes, including in the 30- to 120-minute window, higher likelihood of achieving discharge to home (absolute increase, 2.13% [95% CI, 0.81%-3.44%]) and lower in-hospital mortality/hospice discharge (absolute decrease, -1.48% [95% CI, -2.60% to -0.36%]) for each 15-minute increment.
Among patients with AIS due to large vessel occlusion treated in routine clinical practice, shorter time to endovascular-reperfusion therapy was significantly associated with better outcomes. These findings support efforts to reduce time to hospital and endovascular treatment in patients with stroke.
随机临床试验表明,对于急性缺血性卒中(AIS)中的大血管闭塞,血管内再灌注治疗的益处与时间有关,但它对结果的影响程度以及对常规临床实践的普遍性仍不确定。
描述接受血管内再灌注治疗的 AIS 患者的治疗速度与结局之间的关系。
设计、设置和参与者:这是一项回顾性队列研究,使用 2015 年 1 月至 2016 年 12 月期间从美国 Get With The Guidelines-Stroke 全国质量注册中心前瞻性收集的数据,最终随访时间为 2017 年 4 月 15 日。参与者为 6756 例前循环大血管闭塞 AIS 患者,血管内再灌注治疗的起病至穿刺时间小于或等于 8 小时。
起病(最后一次明确时间)至动脉穿刺时间和医院到达至动脉穿刺时间(门到穿刺时间)。
大量再灌注(改良脑梗死溶栓评分 2b-3)、活动状态、全球残疾(改良 Rankin 量表[mRS])和出院时的去向、症状性颅内出血(sICH)和住院死亡率/临终关怀出院。
在 6756 例患者中,平均(SD)年龄为 69.5(14.8)岁,51.2%(3460/6756)为女性,治疗前 NIH 卒中量表中位数为 17(IQR,12-22)。中位起病至穿刺时间为 230 分钟(IQR,170-305),中位门到穿刺时间为 87 分钟(IQR,62-116),6324 例(85.9%)患者实现了大量再灌注。6693 例(6.7%)患者发生 sICH,6756 例(19.6%)患者发生住院死亡率/临终关怀出院。出院时,5783 例(36.9%)患者能够独立活动,5334 例(23.0%)患者具有功能独立性(mRS 0-2)。在起病至穿刺时间调整分析中,时间-结局关系是非线性的,30 至 270 分钟之间的斜率比 271 至 480 分钟之间的斜率更陡峭。在 30 至 270 分钟的时间范围内,每增加 15 分钟的起病至穿刺时间与更高的出院独立活动能力(绝对增加,1.14%[95%CI,0.75%-1.53%])、更低的住院死亡率/临终关怀出院率(绝对降低,-0.77%[95%CI,-1.07%至-0.47%])和更低的 sICH 风险(绝对降低,-0.22%[95%CI,-0.40%至-0.03%])相关。更快的门到穿刺时间也与改善结局相关,包括在 30 至 120 分钟的窗口内,出院回家的可能性更高(绝对增加,2.13%[95%CI,0.81%-3.44%]),住院死亡率/临终关怀出院率更低(绝对降低,-1.48%[95%CI,-2.60%至-0.36%]),每增加 15 分钟。
在接受常规临床实践治疗的大血管闭塞性 AIS 患者中,血管内再灌注治疗时间越短,结局越好。这些发现支持努力减少患者卒中的医院和血管内治疗时间。